Skip to content Skip to footer

Related content

Editorial: Digital twins in medicine-transition from theoretical concept to tool used in everyday care

Gilbert, S., Drummond, D., Cotte, F. & Ziemssen, T., 27 Feb 2025, In: Frontiers in Digital Health. 7, 1573727.

Research output: Contribution to journalEditorial (Lead article)Contributedpeer-review

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension

Cerqueira, J. J., Berthele, A., Cree, B. A. C., Filippi, M., Pardo, G., Pearson, O. R. & Traboulsee, A. & 11 others, Ziemssen, T., Vollmer, T., Bernasconi, C., Mandel, C. R., Kulyk, I., Chognot, C., Raposo, C., Schneble, H.-M., Thanei, G.-A., Incera, E. & Havrdová, E. K., 25 Feb 2025, In: Neurology. 104, 4, e210142.

Research output: Contribution to journalResearch articleContributedpeer-review

A plain language summary of a study exploring the experiences of people with relapsing-remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Barrett, A., Olayinka-Amao, O., Ziemssen, T., Bharadia, T., Henke, C. & Kamudoni, P., Feb 2025, In: Neurodegenerative disease management. p. 1-8 8 p.

Research output: Contribution to journalResearch articleContributedpeer-review

Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint

Demuth, S., De Sèze, J., Edan, G., Ziemssen, T., Simon, F. & Gourraud, P.-A., 28 Jan 2025, In: JMIR medical informatics. 13, e53542.

Research output: Contribution to journalResearch articleContributedpeer-review

Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study

Inojosa, H., Schriefer, D., Ness, N.-H., Dillenseger, A., Akgün, K. & Ziemssen, T., 17 Jan 2025, In: Journal of neurology. 272, 2, 1 p., 153.

Research output: Contribution to journalResearch articleContributedpeer-review